Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG (NVS)
5/24/2013 8:28:41 AM
More...
|
Biogen, Inc. Release: FAMPYRA(TM), the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada
4/11/2012 9:46:17 AM
More...
|
Biogen, Inc. Takes Option to MAKScientific, LLC MS Program
3/15/2012 8:45:06 AM
More...
|
Biogen, Inc. Appoints Kenneth DiPietro Executive Vice President, Human Resources
1/30/2012 6:20:18 AM
More...
|
Biogen, Inc., and Elan Corporation PLC (ELN) Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
1/26/2012 7:16:11 AM
More...
|
Biogen, Inc. to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012
1/17/2012 5:52:36 AM
More...
|
Biogen, Inc. to Present at the Goldman, Sachs & Co. Healthcare CEOs Unscripted Conference
12/29/2011 5:56:48 AM
More...
|
Biogen, Inc. Reports Third Quarter 2011 Results
10/28/2011 7:40:00 AM
More...
|
Biogen, Inc. to Close Sites, Cut 650 Jobs
11/3/2010 6:41:50 AM
More...
|
Biogen, Inc. to Implement Restructuring Program; to Cut Jobs
10/25/2010 7:04:27 AM
More...
|
|